ONCO

10-Q - Onconetix, Inc. (0001782107) (Filer)

S-1 - Onconetix, Inc. (0001782107) (Filer)

Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Company"), a leader in humanoid robotics and embodied AI, reports its interim financial results for the three and nine months ended June 30, 2026 ("Q3-2026"). All dollar figures are reported in United States dollars ("USD"), unless otherwise stated. Realbotix Corp. is a holding company with two independently operated subsidiaries, Realbotix LLC and Intima LLC. While both leverage embedded AI and robotics, they offer distinct end products to different customer bases. Each maintains its own management, personnel, payroll, facilities, manufacturing operations, product development, and go-to-market strategies.

425 - Onconetix, Inc. (0001782107) (Subject)

Entertainment Industry Agreement Reflects Real-World Adoption of Humanoid Robotics Technology Across Education, Healthcare, Hospitality, and Customer Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix’s previously announced pending acquisition. Realbotix has entered into an agreement with a recognized streaming platform to feature one of its humanoid robots as a

Proteomedix Co-Founder and Proclarix® Co-Developer Returns to Company’s Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") today announced that its fully-owned Swiss subsidiary, Proteomedix AG ("PMX"), has appointed Ralph Schiess, PhD to the PMX Board of Directors. The appointment was approved at the PMX Annual General Meeting of Shareholders held on June 22, 2026, at which Thomas Meier, PhD was also re-elected to serve an additional one-year term as Chairman of the Board. Dr. Schiess is a co-founder of Proteomedix AG and co-developer of Proclarix®, th

8-K - Onconetix, Inc. (0001782107) (Filer)

Commercial robotics and online consumer businesses maintain separate management, personnel, operations and product strategies Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Company") provides an overview of its corporate and operating structure. Realbotix Corp. is a holding company with two separately operated businesses: Realbotix LLC, which focuses on AI-powered humanoid robotics for commercial service sector applications, and Intima LLC, which focuses on direct-to-consumer products. Realbotix LLC and Intima LLC have different product offerings with no crossover. As a holding company, Realbotix Corp. does not in itself have business operations but is

425 - Onconetix, Inc. (0001782107) (Subject)

Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve Wellbeing and Address Loneliness Among Older Adults in UK Care Settings; Realbotix Becomes Accredited Supplier on Bloom’s Public Sector Marketplace; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, July 07, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix’s previously announced pending acquisition. Realbotix has announced a partnership with Bloom Procu

425 - Onconetix, Inc. (0001782107) (Subject)

Salamanca City Central School District on Seneca Nation Reservation to Deploy Optio and Realbotix M-Series Humanoid Robot; Pilot to Expand to Approximately 500 High School Students in Fall 2026; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, June 24, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix’s previously announced pending acquisition. Realbotix has launched Optio, its AI-powered teacher’s assistant, in a pilot program a

424B3 - Onconetix, Inc. (0001782107) (Filer)

EFFECT - Onconetix, Inc. (0001782107) (Filer)

Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Company"), a leading developer of humanoid robots and AI systems designed for human interaction across enterprise and consumer environments, reports its interim financial results for the three and six months ended March 31, 2026 ("Q2-2026"). All dollar figures are reported in United States dollars ("USD"), unless otherwise stated. Q2-2026 Financial and Operating Highlights For the three and six months ended March 31, 2026, the Company generated revenue of $225,000 and $578,000, respectively, compared to $727,000 and $1,543,000 for the corresponding periods in the prior fiscal year. The decline in revenue i

8-K - Onconetix, Inc. (0001782107) (Filer)

CINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology, today announced that its Board of Directors (the "Board of Directors" or "Board") has approved a 1-for-10 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on May 21, 2026. On April 30, 2026, Onconetix held a special meeting of stockholders (the "Special Meeting"), at which the Company's stockholders approved a proposal to effect one or more reverse splits, at a ratio in the range of

Transaction to take Realbotix LLC, a premier social humanoid robot company, to the Nasdaq Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Parent Company"), a leading AI humanoid robot manufacturer for social tasks, is pleased to provide an update on its previously announced transaction to list Realbotix LLC ("RealLLC" or the "Subsidiary"), a wholly owned subsidiary of Realbotix, on the Nasdaq Capital Market via a reverse takeover transaction with Onconetix, Inc. (NASDAQ:ONCO) ("ONCO"). The proposed transaction will result in the robotics and AI business of RealLLC to be listed on Nasdaq, with the Parent Company (Realbotix) maintaining a 75–90% ownership

8-K - Onconetix, Inc. (0001782107) (Filer)

New Clinical Data Reinforce Proclarix® Performance in Reducing Overdiagnosis and Unnecessary Biopsies; Multi-Center PRIME Study Initiated in Collaboration with Labcorp; European Commercial Expansion Advances CINCINNATI, Ohio, May 13, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") today provided an update on the Q1 2026 operational progress of its fully-owned Swiss subsidiary, Proteomedix AG ("PMX"), developer of Proclarix®, a CE-IVD certified diagnostic blood test used in combination with PSA (prostate-specific antigen) to identify clinically significant prostate cancer ("csPCa"). Prostate cancer is the most frequently diagnosed male cancer in most

10-Q - Onconetix, Inc. (0001782107) (Filer)

EFFECT - Onconetix, Inc. (0001782107) (Filer)

EFFECT - Onconetix, Inc. (0001782107) (Filer)

S-1/A - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)